{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:14:00Z","timestamp":1787163240412,"version":"build-2736575974"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-026-03089-2","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T14:44:16Z","timestamp":1769784256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["World free HIV: the novel therapeutic approaches for eliminating latent HIV infection"],"prefix":"10.1186","volume":"23","author":[{"given":"Akmal","family":"Zubair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Bibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M.","family":"Alkahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Yaqoob","family":"Shahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naila","family":"Afghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"17","key":"3089_CR1","doi-asserted-by":"publisher","first-page":"9105","DOI":"10.1128\/JVI.78.17.9105-9114.2004","volume":"78","author":"KG Lassen","year":"2004","unstructured":"Lassen KG, Bailey JR, Siliciano RF. Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4\u2009+\u2009T cells in vivo. J Virol. 2004;78(17):9105\u201314.","journal-title":"J Virol"},{"issue":"7037","key":"3089_CR2","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/nature03513","volume":"434","author":"Q Li","year":"2005","unstructured":"Li Q, et al. Peak SIV replication in resting memory CD4\u2009+\u2009T cells depletes gut lamina propria CD4\u2009+\u2009T cells. Nature. 2005;434(7037):1148\u201352.","journal-title":"Nature"},{"issue":"5","key":"3089_CR3","doi-asserted-by":"publisher","first-page":"e70121","DOI":"10.1111\/cbdd.70121","volume":"105","author":"A Zubair","year":"2025","unstructured":"Zubair A, et al. Current challenges with highly active antiretroviral therapy and new hope and horizon with CRISPR-CAS9 technology for HIV treatment. Chem Biol Drug Des. 2025;105(5):e70121.","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"3089_CR4","doi-asserted-by":"publisher","first-page":"5549074","DOI":"10.1155\/arat\/5549074","volume":"2025","author":"A Zubair","year":"2025","unstructured":"Zubair A, et al. Assessment of HIV infection in HIV patients admitted to Pakistan Institute of medical Sciences, Islamabad, Pakistan. AIDS Res Treat. 2025;2025(1):5549074.","journal-title":"AIDS Res Treat"},{"key":"3089_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1742-4690-5-107","volume":"5","author":"M Fischer","year":"2008","unstructured":"Fischer M, et al. Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology. 2008;5:107.","journal-title":"Retrovirology"},{"issue":"15","key":"3089_CR6","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1073\/pnas.0308425101","volume":"101","author":"ZQ Zhang","year":"2004","unstructured":"Zhang ZQ, et al. Roles of substrate availability and infection of resting and activated CD4\u2009+\u2009T cells in transmission and acute Simian immunodeficiency virus infection. Proc Natl Acad Sci U S A. 2004;101(15):5640\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3089_CR7","doi-asserted-by":"publisher","first-page":"43984","DOI":"10.1038\/s41598-025-27720-4","volume":"15","author":"A Zubair","year":"2025","unstructured":"Zubair A, et al. Molecular assessment of the HIV pol gene and use of computational vaccine design targeting Pakistani isolates. Sci Rep. 2025;15(1):43984.","journal-title":"Sci Rep"},{"issue":"1","key":"3089_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s11033-025-10993-3","volume":"52","author":"A Zubair","year":"2025","unstructured":"Zubair A, et al. Unlocking the role of transcription activator-like effector nuclease (TALENs) and zinc finger nuclease (ZFN) in the treatment of HIV. Mol Biol Rep. 2025;52(1):948.","journal-title":"Mol Biol Rep"},{"issue":"3","key":"3089_CR9","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1128\/JVI.80.3.1599-1603.2006","volume":"80","author":"PA Arlen","year":"2006","unstructured":"Arlen PA, et al. Rapid expression of human immunodeficiency virus following activation of latently infected cells. J Virol. 2006;80(3):1599\u2013603.","journal-title":"J Virol"},{"issue":"24","key":"3089_CR10","doi-asserted-by":"publisher","first-page":"13938","DOI":"10.1128\/JVI.01745-07","volume":"81","author":"G Plesa","year":"2007","unstructured":"Plesa G, et al. Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4\u2009+\u2009T cells. J Virol. 2007;81(24):13938\u201342.","journal-title":"J Virol"},{"issue":"2","key":"3089_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.virol.2005.09.063","volume":"344","author":"N Selliah","year":"2006","unstructured":"Selliah N, et al. The gammac-cytokine regulated transcription factor, STAT5, increases HIV-1 production in primary CD4 T cells. Virology. 2006;344(2):283\u201391.","journal-title":"Virology"},{"key":"3089_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70024","author":"A Zubair","year":"2025","unstructured":"Zubair A, et al. mRNA vaccines against HIV: hopes and challenges. HIV Med. 2025. https:\/\/doi.org\/10.1111\/hiv.70024.","journal-title":"HIV Med"},{"issue":"2","key":"3089_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2174\/1570162043484915","volume":"2","author":"DH Hamer","year":"2004","unstructured":"Hamer DH. Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it. Curr HIV Res. 2004;2(2):99\u2013111.","journal-title":"Curr HIV Res"},{"issue":"9883","key":"3089_CR14","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/S0140-6736(13)60104-X","volume":"381","author":"C Katlama","year":"2013","unstructured":"Katlama C, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013;381(9883):2109\u201317.","journal-title":"Lancet"},{"issue":"5","key":"3089_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/jmp.12613","volume":"51","author":"K Tanaka","year":"2022","unstructured":"Tanaka K, et al. The role of latency reversal in HIV cure strategies. J Med Primatol. 2022;51(5):278\u201383.","journal-title":"J Med Primatol"},{"issue":"9","key":"3089_CR16","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1097\/QAD.0000000000001064","volume":"30","author":"C Guti\u00e9rrez","year":"2016","unstructured":"Guti\u00e9rrez C, et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. Aids. 2016;30(9):1385\u201392.","journal-title":"Aids"},{"issue":"12","key":"3089_CR17","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1016\/S2352-3018(15)00226-X","volume":"2","author":"JH Elliott","year":"2015","unstructured":"Elliott JH, et al. Short-term administration of Disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV. 2015;2(12):e520\u20139.","journal-title":"Lancet HIV"},{"issue":"9","key":"3089_CR18","doi-asserted-by":"publisher","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","volume":"11","author":"OS S\u00f8gaard","year":"2015","unstructured":"S\u00f8gaard OS, et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 2015;11(9):e1005142.","journal-title":"PLoS Pathog"},{"issue":"10227","key":"3089_CR19","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0140-6736(19)32990-3","volume":"395","author":"S Fidler","year":"2020","unstructured":"Fidler S, et al. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet. 2020;395(10227):888\u201398.","journal-title":"Lancet"},{"key":"3089_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.virol.2014.02.008","volume":"454\u20135","author":"U Mbonye","year":"2014","unstructured":"Mbonye U, Karn J. Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virol. 2014;454\u20135:328\u201339.","journal-title":"Virol"},{"issue":"4","key":"3089_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","volume":"27","author":"LB Cohn","year":"2020","unstructured":"Cohn LB, Chomont N, Deeks SG. The biology of the HIV-1 latent reservoir and implications for cure strategies. Cell Host Microbe. 2020;27(4):519\u201330.","journal-title":"Cell Host Microbe"},{"issue":"3","key":"3089_CR22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","volume":"155","author":"YC Ho","year":"2013","unstructured":"Ho YC, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155(3):540\u201351.","journal-title":"Cell"},{"issue":"4","key":"3089_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nm.3489","volume":"20","author":"CK Bullen","year":"2014","unstructured":"Bullen CK, et al. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014;20(4):425\u20139.","journal-title":"Nat Med"},{"issue":"5","key":"3089_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","volume":"48","author":"S Sengupta","year":"2018","unstructured":"Sengupta S, Siliciano RF. Targeting the latent reservoir for HIV-1. Immunity. 2018;48(5):872\u201395.","journal-title":"Immunity"},{"issue":"18","key":"3089_CR25","doi-asserted-by":"publisher","first-page":"10803","DOI":"10.1128\/JVI.00320-14","volume":"88","author":"MB Lucera","year":"2014","unstructured":"Lucera MB, et al. The histone deacetylase inhibitor Vorinostat (SAHA) increases the susceptibility of uninfected CD4\u2009+\u2009T cells to HIV by increasing the kinetics and efficiency of postentry viral events. J Virol. 2014;88(18):10803\u201312.","journal-title":"J Virol"},{"issue":"17","key":"3089_CR26","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1021\/jm990613q","volume":"43","author":"H Tamamura","year":"2000","unstructured":"Tamamura H, et al. Conformationally constrained analogues of Diacylglycerol (DAG). 17. Contrast between sn-1 and sn-2 DAG lactones in binding to protein kinase C. J Med Chem. 2000;43(17):3209\u201317.","journal-title":"J Med Chem"},{"issue":"1","key":"3089_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1074\/jbc.RA118.005798","volume":"294","author":"K Matsuda","year":"2019","unstructured":"Matsuda K, et al. Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal. J Biol Chem. 2019;294(1):116\u201329.","journal-title":"J Biol Chem"},{"issue":"5","key":"3089_CR28","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1172\/JCI80142","volume":"125","author":"GM Laird","year":"2015","unstructured":"Laird GM, et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest. 2015;125(5):1901\u201312.","journal-title":"J Clin Invest"},{"issue":"7","key":"3089_CR29","doi-asserted-by":"publisher","first-page":"e1005066","DOI":"10.1371\/journal.ppat.1005066","volume":"11","author":"G Jiang","year":"2015","unstructured":"Jiang G, et al. Synergistic reactivation of latent HIV expression by Ingenol-3-Angelate, PEP005, targeted NF-kB signaling in combination with JQ1 induced p-TEFb activation. PLoS Pathog. 2015;11(7):e1005066.","journal-title":"PLoS Pathog"},{"key":"3089_CR30","doi-asserted-by":"publisher","first-page":"e34655","DOI":"10.7554\/eLife.34655","volume":"7","author":"E Battivelli","year":"2018","unstructured":"Battivelli E, et al. Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4(+) T cells. Elife. 2018;7:e34655 https:\/\/doi.org\/10.7554\/eLife.34655.","journal-title":"Elife"},{"issue":"3","key":"3089_CR31","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1172\/JCI124291","volume":"129","author":"KB Einkauf","year":"2019","unstructured":"Einkauf KB, et al. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. J Clin Invest. 2019;129(3):988\u201398.","journal-title":"J Clin Invest"},{"issue":"9","key":"3089_CR32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.4156","volume":"22","author":"KM Bruner","year":"2016","unstructured":"Bruner KM, et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med. 2016;22(9):1043\u20139.","journal-title":"Nat Med"},{"issue":"9485","key":"3089_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(05)67098-5","volume":"366","author":"G Lehrman","year":"2005","unstructured":"Lehrman G, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005;366(9485):549\u201355.","journal-title":"Lancet"},{"issue":"6","key":"3089_CR34","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1086\/511823","volume":"195","author":"JD Siliciano","year":"2007","unstructured":"Siliciano JD, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis. 2007;195(6):833\u20136.","journal-title":"J Infect Dis"},{"issue":"10","key":"3089_CR35","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/QAD.0b013e3282fd6ddc","volume":"22","author":"N Sagot-Lerolle","year":"2008","unstructured":"Sagot-Lerolle N, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. Aids. 2008;22(10):1125\u20139.","journal-title":"Aids"},{"issue":"5","key":"3089_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1468-1293.2011.00975.x","volume":"13","author":"JP Routy","year":"2012","unstructured":"Routy JP, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012;13(5):291\u20136.","journal-title":"HIV Med"},{"issue":"8","key":"3089_CR37","doi-asserted-by":"publisher","first-page":"100122","DOI":"10.1016\/j.crmeth.2021.100122","volume":"1","author":"K Matsuda","year":"2021","unstructured":"Matsuda K, et al. A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro. Cell Rep Methods. 2021;1(8):100122.","journal-title":"Cell Rep Methods"},{"key":"3089_CR38","doi-asserted-by":"crossref","unstructured":"Vicenti I et al. Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells. J Gen Virol. 2021;102(1).","DOI":"10.1099\/jgv.0.001499"},{"issue":"2","key":"3089_CR39","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/10409238.2018.1442408","volume":"53","author":"AC Newton","year":"2018","unstructured":"Newton AC. Protein kinase c: perfectly balanced. Crit Rev Biochem Mol Biol. 2018;53(2):208\u201330.","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"3","key":"3089_CR40","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s11262-025-02149-z","volume":"61","author":"A Zubair","year":"2025","unstructured":"Zubair A, et al. Molecular characterization and drug resistance pattern in pol gene of HIV-1 sub-subtypes Circulating in Lahore, Pakistan. Virus Genes. 2025;61(3):324\u201341.","journal-title":"Virus Genes"},{"issue":"13","key":"3089_CR41","doi-asserted-by":"publisher","first-page":"7847","DOI":"10.1016\/S0021-9258(18)34459-4","volume":"257","author":"M Castagna","year":"1982","unstructured":"Castagna M, et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 1982;257(13):7847\u201351.","journal-title":"J Biol Chem"},{"issue":"12","key":"3089_CR42","doi-asserted-by":"publisher","first-page":"e1003834","DOI":"10.1371\/journal.ppat.1003834","volume":"9","author":"CA Spina","year":"2013","unstructured":"Spina CA, et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4\u2009+\u2009T cells from aviremic patients. PLoS Pathog. 2013;9(12):e1003834.","journal-title":"PLoS Pathog"},{"issue":"40","key":"3089_CR43","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.1074\/jbc.M402124200","volume":"279","author":"SA Williams","year":"2004","unstructured":"Williams SA, et al. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem. 2004;279(40):42008\u201317.","journal-title":"J Biol Chem"},{"issue":"5","key":"3089_CR44","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/088922204323087741","volume":"20","author":"J Kulkosky","year":"2004","unstructured":"Kulkosky J, et al. Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. AIDS Res Hum Retroviruses. 2004;20(5):497\u2013505.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"3089_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0166-3542(03)00034-2","volume":"59","author":"S Bocklandt","year":"2003","unstructured":"Bocklandt S, Blumberg PM, Hamer DH. Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. Antiviral Res. 2003;59(2):89\u201398.","journal-title":"Antiviral Res"},{"issue":"12","key":"3089_CR46","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1084\/jem.20081398","volume":"205","author":"RB Jones","year":"2008","unstructured":"Jones RB, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205(12):2763\u201379.","journal-title":"J Exp Med"},{"key":"3089_CR47","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126027","author":"G Jiang","year":"2019","unstructured":"Jiang G, et al. Disruption of latent HIV in vivo during the clearance of actinic keratosis by ingenol mebutate. JCI Insight. 2019. https:\/\/doi.org\/10.1172\/jci.insight.126027.","journal-title":"JCI Insight"},{"issue":"11","key":"3089_CR48","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1097\/QAD.0000000000000289","volume":"28","author":"G Jiang","year":"2014","unstructured":"Jiang G, et al. Reactivation of HIV latency by a newly modified ingenol derivative via protein kinase C\u03b4-NF-\u03baB signaling. Aids. 2014;28(11):1555\u201366.","journal-title":"Aids"},{"issue":"1","key":"3089_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/QAD.0000000000001267","volume":"31","author":"L Gama","year":"2017","unstructured":"Gama L, et al. Reactivation of Simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. Aids. 2017;31(1):5\u201314.","journal-title":"Aids"},{"issue":"39","key":"3089_CR50","doi-asserted-by":"publisher","first-page":"27981","DOI":"10.1074\/jbc.274.39.27981","volume":"274","author":"X Yang","year":"1999","unstructured":"Yang X, Chen Y, Gabuzda D. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappaB. J Biol Chem. 1999;274(39):27981\u20138.","journal-title":"J Biol Chem"},{"issue":"2","key":"3089_CR51","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0092-8674(00)81842-5","volume":"88","author":"FS Lee","year":"1997","unstructured":"Lee FS, et al. Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell. 1997;88(2):213\u201322.","journal-title":"Cell"},{"issue":"11","key":"3089_CR52","doi-asserted-by":"publisher","first-page":"e0208055","DOI":"10.1371\/journal.pone.0208055","volume":"13","author":"DC Cary","year":"2018","unstructured":"Cary DC, Peterlin BM. Procyanidin trimer C1 reactivates latent HIV as a triple combination therapy with Kansui and JQ1. PLoS One. 2018;13(11):e0208055.","journal-title":"PLoS One"},{"issue":"3","key":"3089_CR53","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc1819","volume":"6","author":"M Cully","year":"2006","unstructured":"Cully M, et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6(3):184\u201392.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3089_CR54","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.imlet.2007.12.008","volume":"116","author":"MM Juntilla","year":"2008","unstructured":"Juntilla MM, Koretzky GA. Critical roles of the PI3K\/Akt signaling pathway in T cell development. Immunol Lett. 2008;116(2):104\u201310.","journal-title":"Immunol Lett"},{"issue":"2","key":"3089_CR55","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cell.2006.04.006","volume":"125","author":"DJ Rossi","year":"2006","unstructured":"Rossi DJ, Weissman IL. Pten, tumorigenesis, and stem cell self-renewal. Cell. 2006;125(2):229\u201331.","journal-title":"Cell"},{"key":"3089_CR56","first-page":"p5173205","volume":"2016","author":"D Chen","year":"2016","unstructured":"Chen D, et al. HMBA enhances Prostratin-Induced activation of latent HIV-1 via suppressing the expression of negative feedback regulator A20\/TNFAIP3 in NF-\u03baB signaling. Biomed Res Int. 2016;2016:p5173205.","journal-title":"Biomed Res Int"},{"issue":"10","key":"3089_CR57","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1371\/journal.ppat.0030146","volume":"3","author":"X Contreras","year":"2007","unstructured":"Contreras X, et al. HMBA releases P-TEFb from HEXIM1 and 7SK SnRNA via PI3K\/Akt and activates HIV transcription. PLoS Pathog. 2007;3(10):1459\u201369.","journal-title":"PLoS Pathog"},{"issue":"11","key":"3089_CR58","doi-asserted-by":"publisher","first-page":"eaam7341","DOI":"10.1101\/cshperspect.a008730","volume":"2","author":"J Silke","year":"2013","unstructured":"Silke J, Meier P. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold Spring Harb Perspect Biol. 2013;2(11):eaam7341. https:\/\/doi.org\/10.1101\/cshperspect.a008730.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3089_CR59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1615\/CritRevOncog.2016016918","volume":"21","author":"A Philchenkov","year":"2016","unstructured":"Philchenkov A, Miura K. The IAP protein family, SMAC mimetics and cancer treatment. Crit Reviews\u2122 Oncog. 2016;21:3\u20134.","journal-title":"Crit Reviews\u2122 Oncog"},{"issue":"9","key":"3089_CR60","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri.2017.52","volume":"17","author":"SC Sun","year":"2017","unstructured":"Sun SC. The non-canonical NF-\u03baB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545\u201358.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"3089_CR61","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.chom.2015.08.009","volume":"18","author":"L Pache","year":"2015","unstructured":"Pache L, et al. BIRC2\/cIAP1 is a negative regulator of HIV-1 transcription and can be targeted by Smac mimetics to promote reversal of viral latency. Cell Host Microbe. 2015;18(3):345\u201353.","journal-title":"Cell Host Microbe"},{"issue":"3","key":"3089_CR62","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.xcrm.2020.100037","volume":"1","author":"L Pache","year":"2020","unstructured":"Pache L, et al. Pharmacological activation of Non-canonical NF-\u03baB signaling activates latent HIV-1 reservoirs in vivo. Cell Rep Med. 2020;1(3):100037.","journal-title":"Cell Rep Med"},{"issue":"7793","key":"3089_CR63","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-020-1951-3","volume":"578","author":"CC Nixon","year":"2020","unstructured":"Nixon CC, et al. Systemic HIV and SIV latency reversal via non-canonical NF-\u03baB signalling in vivo. Nature. 2020;578(7793):160\u20135.","journal-title":"Nature"},{"key":"3089_CR64","doi-asserted-by":"publisher","first-page":"780400","DOI":"10.3389\/fimmu.2021.780400","volume":"12","author":"B Molyer","year":"2021","unstructured":"Molyer B, Kumar A, Angel JB. SMAC mimetics as therapeutic agents in HIV infection. Front Immunol. 2021;12:780400.","journal-title":"Front Immunol"},{"issue":"10","key":"3089_CR65","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41591-023-02570-7","volume":"29","author":"A Dashti","year":"2023","unstructured":"Dashti A, et al. AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques. Nat Med. 2023;29(10):2535\u201346.","journal-title":"Nat Med"},{"key":"3089_CR66","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fmicb.2018.02022","volume":"9","author":"SI Hattori","year":"2018","unstructured":"Hattori SI, et al. Combination of a Latency-Reversing agent with a Smac mimetic minimizes secondary HIV-1 infection in vitro. Front Microbiol. 2018;9:2022.","journal-title":"Front Microbiol"},{"issue":"3","key":"3089_CR67","doi-asserted-by":"publisher","first-page":"e0317382","DOI":"10.1371\/journal.pone.0317382","volume":"20","author":"A Zubair","year":"2025","unstructured":"Zubair A, et al. Targeting HIV-1 conserved regions: an immunoinformatic pathway to vaccine innovation for the Asia. PLoS One. 2025;20(3):e0317382.","journal-title":"PLoS One"},{"issue":"6309","key":"3089_CR68","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1126\/science.aag1276","volume":"354","author":"SN Byrareddy","year":"2016","unstructured":"Byrareddy SN, et al. Sustained virologic control in SIV\u2009+\u2009macaques after antiretroviral and \u03b14\u03b27 antibody therapy. Science. 2016;354(6309):197\u2013202.","journal-title":"Science"},{"issue":"5","key":"3089_CR69","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10142-024-01425-9","volume":"24","author":"A Zubair","year":"2024","unstructured":"Zubair A, et al. Clinical trials and recent progress in HIV vaccine development. Funct Integr Genomics. 2024;24(5):143.","journal-title":"Funct Integr Genomics"},{"issue":"5","key":"3089_CR70","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/mi.2009.90","volume":"2","author":"M Kader","year":"2009","unstructured":"Kader M, et al. Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol. 2009;2(5):439\u201349.","journal-title":"Mucosal Immunol"},{"key":"3089_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aam7341","author":"C Guzzo","year":"2017","unstructured":"Guzzo C, et al. Virion incorporation of integrin \u03b14\u03b27 facilitates HIV-1 infection and intestinal homing. Sci Immunol. 2017. https:\/\/doi.org\/10.1126\/sciimmunol.aam7341.","journal-title":"Sci Immunol"},{"issue":"3","key":"3089_CR72","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","volume":"36","author":"L Shan","year":"2012","unstructured":"Shan L, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012;36(3):491\u2013501.","journal-title":"Immunity"},{"issue":"5","key":"3089_CR73","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/8400","volume":"5","author":"CJ Pitcher","year":"1999","unstructured":"Pitcher CJ, et al. HIV-1-specific CD4\u2009+\u2009T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 1999;5(5):518\u201325.","journal-title":"Nat Med"},{"issue":"8","key":"3089_CR74","doi-asserted-by":"publisher","first-page":"6715","DOI":"10.1128\/JVI.73.8.6715-6720.1999","volume":"73","author":"SA Kalams","year":"1999","unstructured":"Kalams SA, et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol. 1999;73(8):6715\u201320.","journal-title":"J Virol"},{"issue":"12","key":"3089_CR75","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1084\/jem.188.12.2205","volume":"188","author":"AJ Zajac","year":"1998","unstructured":"Zajac AJ, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188(12):2205\u201313.","journal-title":"J Exp Med"},{"issue":"12","key":"3089_CR76","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1097\/QAD.0000000000000314","volume":"28","author":"LR Cockerham","year":"2014","unstructured":"Cockerham LR, et al. Programmed death-1 expression on CD4\u207a and CD8\u207a T cells in treated and untreated HIV disease. Aids. 2014;28(12):1749\u201358.","journal-title":"Aids"},{"issue":"8","key":"3089_CR77","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"key":"3089_CR78","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto M, et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med. 2018;69:301\u201318.","journal-title":"Annu Rev Med"},{"key":"3089_CR79","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.virol.2014.12.033","volume":"479\u2013480","author":"SM Kahan","year":"2015","unstructured":"Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. Virology. 2015;479\u2013480:180\u201393.","journal-title":"Virology"},{"issue":"4","key":"3089_CR80","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry EJ, et al. Molecular signature of CD8\u2009+\u2009T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670\u201384.","journal-title":"Immunity"},{"issue":"39","key":"3089_CR81","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1073\/pnas.0801497105","volume":"105","author":"SD Blackburn","year":"2008","unstructured":"Blackburn SD, et al. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 Blockade. Proc Natl Acad Sci U S A. 2008;105(39):15016\u201321.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7620","key":"3089_CR82","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im SJ, et al. Defining CD8\u2009+\u2009T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417\u201321.","journal-title":"Nature"},{"issue":"5","key":"3089_CR83","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1371\/journal.pmed.0050100","volume":"5","author":"H Streeck","year":"2008","unstructured":"Streeck H, et al. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8\u2009+\u2009T cells. PLoS Med. 2008;5(5):e100.","journal-title":"PLoS Med"},{"issue":"373","key":"3089_CR84","doi-asserted-by":"publisher","first-page":"eaag2285","DOI":"10.1126\/scitranslmed.aag2285","volume":"9","author":"C Petrovas","year":"2017","unstructured":"Petrovas C, et al. Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Sci Transl Med. 2017;9(373):eaag2285. https:\/\/doi.org\/10.1126\/scitranslmed.aag2285.","journal-title":"Sci Transl Med"},{"issue":"7","key":"3089_CR85","doi-asserted-by":"publisher","first-page":"e1005761","DOI":"10.1371\/journal.ppat.1005761","volume":"12","author":"R Fromentin","year":"2016","unstructured":"Fromentin R, et al. CD4\u2009+\u2009T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. PLoS Pathog. 2016;12(7):e1005761.","journal-title":"PLoS Pathog"},{"issue":"11","key":"3089_CR86","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/infdis\/jix191","volume":"215","author":"CL Gay","year":"2017","unstructured":"Gay CL, et al. Clinical trial of the Anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy. J Infect Dis. 2017;215(11):1725\u201333.","journal-title":"J Infect Dis"},{"issue":"5362","key":"3089_CR87","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1126\/science.280.5362.427","volume":"280","author":"RS Veazey","year":"1998","unstructured":"Veazey RS, et al. Gastrointestinal tract as a major site of CD4\u2009+\u2009T cell depletion and viral replication in SIV infection. Science. 1998;280(5362):427\u201331.","journal-title":"Science"},{"issue":"5","key":"3089_CR88","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1086\/527324","volume":"197","author":"TW Chun","year":"2008","unstructured":"Chun TW, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008;197(5):714\u201320.","journal-title":"J Infect Dis"},{"issue":"10","key":"3089_CR89","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.1128\/JVI.02409-10","volume":"85","author":"P Lerner","year":"2011","unstructured":"Lerner P, et al. The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. J Virol. 2011;85(10):4772\u201382.","journal-title":"J Virol"},{"issue":"10","key":"3089_CR90","doi-asserted-by":"publisher","first-page":"E1126","DOI":"10.1073\/pnas.1414926112","volume":"112","author":"MK Rothenberger","year":"2015","unstructured":"Rothenberger MK, et al. Large number of rebounding\/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci U S A. 2015;112(10):E1126\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"3089_CR91","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1038\/nm.2934","volume":"18","author":"Y Fukazawa","year":"2012","unstructured":"Fukazawa Y, et al. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med. 2012;18(11):1673\u201381.","journal-title":"Nat Med"},{"issue":"1","key":"3089_CR92","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1084\/jem.20121932","volume":"210","author":"M Perreau","year":"2013","unstructured":"Perreau M, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med. 2013;210(1):143\u201356.","journal-title":"J Exp Med"},{"issue":"4","key":"3089_CR93","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cell.2016.06.039","volume":"166","author":"EA Boritz","year":"2016","unstructured":"Boritz EA, et al. Multiple origins of virus persistence during natural control of HIV infection. Cell. 2016;166(4):1004\u201315.","journal-title":"Cell"},{"issue":"2","key":"3089_CR94","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nm.3781","volume":"21","author":"Y Fukazawa","year":"2015","unstructured":"Fukazawa Y, et al. B cell follicle sanctuary permits persistent productive Simian immunodeficiency virus infection in elite controllers. Nat Med. 2015;21(2):132\u20139.","journal-title":"Nat Med"},{"issue":"12","key":"3089_CR95","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1016\/j.celrep.2017.11.075","volume":"21","author":"MA Reuter","year":"2017","unstructured":"Reuter MA, et al. HIV-Specific CD8(+) T cells exhibit reduced and differentially regulated cytolytic activity in lymphoid tissue. Cell Rep. 2017;21(12):3458\u201370.","journal-title":"Cell Rep"},{"issue":"4","key":"3089_CR96","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/mi.2016.100","volume":"10","author":"BE Kiniry","year":"2017","unstructured":"Kiniry BE, et al. Predominance of weakly cytotoxic, T-bet(Low)Eomes(Neg) CD8(+) T-cells in human Gastrointestinal mucosa: implications for HIV infection. Mucosal Immunol. 2017;10(4):1008\u201320.","journal-title":"Mucosal Immunol"},{"issue":"8","key":"3089_CR97","doi-asserted-by":"publisher","first-page":"e02166","DOI":"10.1128\/JVI.02166-16","volume":"91","author":"A Tsai","year":"2017","unstructured":"Tsai A, et al. Toll-like receptor 7 agonist GS-9620 induces HIV expression and HIV-specific immunity in cells from HIV-infected individuals on suppressive antiretroviral therapy. J Virol. 2017;91(8):e02166-16. https:\/\/doi.org\/10.1128\/JVI.02166-16.","journal-title":"J Virol"},{"issue":"18","key":"3089_CR98","doi-asserted-by":"publisher","first-page":"9631","DOI":"10.1128\/JVI.01454-15","volume":"89","author":"VE Walker-Sperling","year":"2015","unstructured":"Walker-Sperling VE, et al. Reactivation kinetics of HIV-1 and susceptibility of reactivated latently infected CD4\u2009+\u2009T cells to HIV-1-Specific CD8\u2009+\u2009T cells. J Virol. 2015;89(18):9631\u20138.","journal-title":"J Virol"},{"issue":"8","key":"3089_CR99","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1086\/529525","volume":"197","author":"SK Choudhary","year":"2008","unstructured":"Choudhary SK, Archin NM, Margolis DM. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J Infect Dis. 2008;197(8):1162\u201370.","journal-title":"J Infect Dis"},{"issue":"5","key":"3089_CR100","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.4049\/jimmunol.1901191","volume":"204","author":"RM Van der Sluis","year":"2020","unstructured":"Van der Sluis RM, et al. Combination immune checkpoint Blockade to reverse HIV latency. J Immunol. 2020;204(5):1242\u201354.","journal-title":"J Immunol"},{"issue":"10","key":"3089_CR101","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1097\/QAD.0000000000002919","volume":"35","author":"JSY Lau","year":"2021","unstructured":"Lau JSY, et al. The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. Aids. 2021;35(10):1631\u20136.","journal-title":"Aids"},{"issue":"5","key":"3089_CR102","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/j.1460-2075.1996.tb00449.x","volume":"15","author":"C Van Lint","year":"1996","unstructured":"Van Lint C, et al. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. Embo J. 1996;15(5):1112\u201320.","journal-title":"Embo J"},{"issue":"22","key":"3089_CR103","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1016\/j.febslet.2011.10.018","volume":"585","author":"W Bernhard","year":"2011","unstructured":"Bernhard W, et al. The Suv39H1 methyltransferase inhibitor Chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett. 2011;585(22):3549\u201354.","journal-title":"FEBS Lett"},{"issue":"2","key":"3089_CR104","doi-asserted-by":"publisher","first-page":"117","DOI":"10.15252\/emmm.201505557","volume":"8","author":"S Bouchat","year":"2016","unstructured":"Bouchat S, et al. Sequential treatment with 5-aza-2\u2019-deoxycytidine and deacetylase inhibitors reactivates HIV-1. EMBO Mol Med. 2016;8(2):117\u201338.","journal-title":"EMBO Mol Med"},{"issue":"8","key":"3089_CR105","doi-asserted-by":"publisher","first-page":"e00888","DOI":"10.1128\/AAC.00888-20","volume":"64","author":"ES Sorensen","year":"2020","unstructured":"Sorensen ES, et al. Structure-activity relationship analysis of benzotriazine analogues as HIV-1 latency-reversing agents. Antimicrob Agents Chemother. 2020;64(8):e00888-20. https:\/\/doi.org\/10.1128\/AAC.00888-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3089_CR106","doi-asserted-by":"publisher","first-page":"16646","DOI":"10.1038\/s41598-017-16816-1","volume":"7","author":"P Lu","year":"2017","unstructured":"Lu P, et al. BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency. Sci Rep. 2017;7(1):16646.","journal-title":"Sci Rep"},{"issue":"1","key":"3089_CR107","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1038\/s41598-017-02634-y","volume":"7","author":"MR L\u00f3pez-Huertas","year":"2017","unstructured":"L\u00f3pez-Huertas MR, et al. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1. Sci Rep. 2017;7(1):2385.","journal-title":"Sci Rep"},{"issue":"9","key":"3089_CR108","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/mt.2016.117","volume":"24","author":"G Geng","year":"2016","unstructured":"Geng G, et al. Development of an attenuated Tat protein as a Highly-effective agent to specifically activate HIV-1 latency. Mol Ther. 2016;24(9):1528\u201337.","journal-title":"Mol Ther"},{"issue":"3","key":"3089_CR109","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/COH.0b013e3283454c39","volume":"6","author":"AR Hersperger","year":"2011","unstructured":"Hersperger AR, et al. Qualitative features of the HIV-specific CD8\u2009+\u2009T-cell response associated with Immunologic control. Curr Opin HIV AIDS. 2011;6(3):169\u201373.","journal-title":"Curr Opin HIV AIDS"},{"issue":"27","key":"3089_CR110","doi-asserted-by":"publisher","first-page":"e38768","DOI":"10.1097\/MD.0000000000038768","volume":"103","author":"EU Alum","year":"2024","unstructured":"Alum EU, et al. Toward a cure - Advancing HIV\/AIDs treatment modalities beyond antiretroviral therapy: A review. Med (Baltim). 2024;103(27):e38768.","journal-title":"Med (Baltim)"},{"issue":"7358","key":"3089_CR111","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature10237","volume":"476","author":"G Alter","year":"2011","unstructured":"Alter G, et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature. 2011;476(7358):96\u2013100.","journal-title":"Nature"},{"issue":"6371","key":"3089_CR112","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aam8825","volume":"359","author":"V Ramsuran","year":"2018","unstructured":"Ramsuran V, et al. Elevated HLA-A expression impairs HIV control through Inhibition of NKG2A-expressing cells. Science. 2018;359(6371):86\u201390.","journal-title":"Science"},{"issue":"11","key":"3089_CR113","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/nm.4421","volume":"23","author":"N Huot","year":"2017","unstructured":"Huot N, et al. Natural killer cells migrate into and control Simian immunodeficiency virus replication in lymph node follicles in African green monkeys. Nat Med. 2017;23(11):1277\u201386.","journal-title":"Nat Med"},{"issue":"7","key":"3089_CR114","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/v16071163","volume":"16","author":"TC Chou","year":"2024","unstructured":"Chou TC, Maggirwar NS, Marsden MD. HIV persistence, latency, and cure approaches: where are we now? Viruses. 2024;16(7):1163 https:\/\/doi.org\/10.3390\/v16071163.","journal-title":"Viruses"},{"issue":"5","key":"3089_CR115","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.3390\/ijms25052621","volume":"25","author":"K Matsuda","year":"2024","unstructured":"Matsuda K, Maeda K. HIV reservoirs and treatment strategies toward curing HIV infection. Int J Mol Sci. 2024;25(5):2621 https:\/\/doi.org\/10.3390\/ijms25052621.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3089_CR116","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/ni1138","volume":"5","author":"A Mart\u00edn-Fontecha","year":"2004","unstructured":"Mart\u00edn-Fontecha A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5(12):1260\u20135.","journal-title":"Nat Immunol"},{"issue":"8","key":"3089_CR117","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1182\/blood-2002-09-2876","volume":"101","author":"TA Fehniger","year":"2003","unstructured":"Fehniger TA, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101(8):3052\u20137.","journal-title":"Blood"},{"key":"3089_CR118","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fimmu.2014.00133","volume":"5","author":"SA Cassidy","year":"2014","unstructured":"Cassidy SA, Cheent KS, Khakoo SI. Effects of peptide on NK cell-mediated MHC I recognition. Front Immunol. 2014;5:133.","journal-title":"Front Immunol"},{"issue":"1","key":"3089_CR119","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4049\/jimmunol.178.1.33","volume":"178","author":"H Thananchai","year":"2007","unstructured":"Thananchai H, et al. Cutting edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol. 2007;178(1):33\u20137.","journal-title":"J Immunol"},{"issue":"6684","key":"3089_CR120","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1126\/science.adk1831","volume":"383","author":"JD Siliciano","year":"2024","unstructured":"Siliciano JD, Siliciano RF. HIV cure: the daunting scale of the problem. Science. 2024;383(6684):703\u20135.","journal-title":"Science"},{"issue":"20","key":"3089_CR121","doi-asserted-by":"publisher","first-page":"10176","DOI":"10.1128\/JVI.01484-15","volume":"89","author":"R Olesen","year":"2015","unstructured":"Olesen R, et al. Innate immune activity correlates with CD4 T Cell-Associated HIV-1 DNA decline during Latency-Reversing treatment with Panobinostat. J Virol. 2015;89(20):10176\u201389.","journal-title":"J Virol"},{"issue":"12","key":"3089_CR122","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/cid\/cix1111","volume":"66","author":"S Hua","year":"2018","unstructured":"Hua S, et al. Pegylated Interferon-\u03b1-Induced natural killer cell activation is associated with human immunodeficiency Virus-1 DNA decline in antiretroviral Therapy-Treated HIV-1\/Hepatitis C Virus-Coinfected patients. Clin Infect Dis. 2018;66(12):1910\u20137.","journal-title":"Clin Infect Dis"},{"issue":"36","key":"3089_CR123","doi-asserted-by":"publisher","first-page":"14725","DOI":"10.1073\/pnas.1110900108","volume":"108","author":"S Lopez-Verg\u00e8s","year":"2011","unstructured":"Lopez-Verg\u00e8s S, et al. Expansion of a unique CD57\u207aNKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A. 2011;108(36):14725\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"3089_CR124","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/ni.3227","volume":"16","author":"RK Reeves","year":"2015","unstructured":"Reeves RK, et al. Antigen-specific NK cell memory in rhesus macaques. Nat Immunol. 2015;16(9):927\u201332.","journal-title":"Nat Immunol"},{"key":"3089_CR125","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fimmu.2017.01143","volume":"8","author":"H Peng","year":"2017","unstructured":"Peng H, Tian Z. Natural killer cell memory: progress and implications. Front Immunol. 2017;8:1143.","journal-title":"Front Immunol"},{"issue":"7408","key":"3089_CR126","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"NM Archin","year":"2012","unstructured":"Archin NM, et al. Administration of Vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487(7408):482\u20135.","journal-title":"Nature"},{"key":"3089_CR127","unstructured":"Lewin S. HIV latency and eradication: clinical perspectives (Abstract 106). in 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA. 2012."},{"key":"3089_CR128","unstructured":"Spivak A et al. Safety and feasibility of using disulfiram to enhance HIV transcription among long-term ARV-treated adults: preliminary results from a pilot study. in 19th conference on retroviruses and opportunistic infections. 2012."},{"issue":"18","key":"3089_CR129","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1097\/QAD.0b013e32834cdaba","volume":"25","author":"D Persaud","year":"2011","unstructured":"Persaud D, et al. Effect of therapeutic HIV Recombinant poxvirus vaccines on the size of the resting CD4\u2009+\u2009T-cell latent HIV reservoir. Aids. 2011;25(18):2227\u201334.","journal-title":"Aids"},{"key":"3089_CR130","unstructured":"June C. Introduction of acquired CCR5 deficiency with zinc finger nuclease-modified autologous CD4 T cells (SB-728-T) correlates with increases in CD4 count and effects on viral load in HIV-infected subjects 19th Conference on Retroviruses and Opportunistic Infections5\u20138 March 2012Seattle. 2012, WA."},{"key":"3089_CR131","unstructured":"Lalezari J et al. A single infusion of zinc finger nuclease CCR5 modified autologous CD4 T cells (SB-728-T) increases CD4 counts and leads to decrease in HIV proviral load in an aviremic HIV-infected subject. in Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA. 2012."},{"issue":"36","key":"3089_CR132","doi-asserted-by":"publisher","first-page":"36ra43","DOI":"10.1126\/scitranslmed.3000931","volume":"2","author":"DL DiGiusto","year":"2010","unstructured":"DiGiusto DL, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med. 2010;2(36):36ra43.","journal-title":"Sci Transl Med"},{"issue":"3","key":"3089_CR133","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.celrep.2017.09.080","volume":"21","author":"CF Kessing","year":"2017","unstructured":"Kessing CF, et al. Vivo suppression of HIV rebound by Didehydro-Cortistatin A, a Block-and-Lock strategy for HIV-1 treatment. Cell Rep. 2017;21(3):600\u201311.","journal-title":"Cell Rep"},{"key":"3089_CR134","doi-asserted-by":"crossref","unstructured":"Margolis DM, Browne EP. The role of Tat in HIV latency and reactivation. Front Immunol, 2025. Volume 16\u20132025.","DOI":"10.3389\/fimmu.2025.1650385"},{"key":"3089_CR135","doi-asserted-by":"crossref","unstructured":"Vargas B, Sluis-Cremer N. Toward a functional cure for HIV-1 infection: the block and lock therapeutic approach. Frontiers in Virology; 2022. pp. 2\u20132022.","DOI":"10.3389\/fviro.2022.917941"},{"issue":"1","key":"3089_CR136","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1038\/s41467-025-59398-7","volume":"16","author":"E Pellaers","year":"2025","unstructured":"Pellaers E, et al. BRD4 modulator ZL0580 and LEDGINs additively block and lock HIV-1 transcription. Nat Commun. 2025;16(1):4226.","journal-title":"Nat Commun"},{"issue":"6","key":"3089_CR137","doi-asserted-by":"publisher","first-page":"107374","DOI":"10.1016\/j.jbc.2024.107374","volume":"300","author":"C Batisse","year":"2024","unstructured":"Batisse C, et al. Integrase-LEDGF\/p75 complex triggers the formation of biomolecular condensates that modulate HIV-1 integration efficiency in vitro. J Biol Chem. 2024;300(6):107374.","journal-title":"J Biol Chem"},{"issue":"2","key":"3089_CR138","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-021-01651-9","volume":"28","author":"JS Miller","year":"2022","unstructured":"Miller JS, et al. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. Nat Med. 2022;28(2):392\u2013400.","journal-title":"Nat Med"},{"issue":"9","key":"3089_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/v15091912","volume":"15","author":"JN Howard","year":"2023","unstructured":"Howard JN, Bosque A. IL-15 and N-803 for HIV cure approaches. Viruses. 2023;15(9):1912.","journal-title":"Viruses"},{"issue":"1","key":"3089_CR140","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12981-025-00734-8","volume":"22","author":"S Mahomed","year":"2025","unstructured":"Mahomed S, et al. Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review. AIDS Res Ther. 2025;22(1):44.","journal-title":"AIDS Res Ther"},{"key":"3089_CR141","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.virusres.2017.07.020","volume":"244","author":"G Wang","year":"2018","unstructured":"Wang G, et al. CRISPR-Cas based antiviral strategies against HIV-1. Virus Res. 2018;244:321\u201332.","journal-title":"Virus Res"},{"issue":"1","key":"3089_CR142","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s10142-025-01613-1","volume":"25","author":"HM Hassan","year":"2025","unstructured":"Hassan HM, et al. New hope and promise with CRISPR-Cas9 technology for the treatment of HIV. Funct Integr Genom. 2025;25(1):108.","journal-title":"Funct Integr Genom"},{"key":"3089_CR143","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00518-16","author":"H Jin","year":"2016","unstructured":"Jin H, et al. Shutdown of HIV-1 transcription in T cells by Nullbasic, a mutant Tat protein. mBio. 2016. https:\/\/doi.org\/10.1128\/mBio.00518-16.","journal-title":"mBio"},{"issue":"5","key":"3089_CR144","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.ymthe.2005.07.524","volume":"12","author":"MJ Li","year":"2005","unstructured":"Li MJ, et al. Long-term Inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther. 2005;12(5):900\u20139.","journal-title":"Mol Ther"},{"issue":"2","key":"3089_CR145","first-page":"66","volume":"1","author":"K Suzuki","year":"2005","unstructured":"Suzuki K, et al. Prolonged transcriptional Silencing and CpG methylation induced by SiRNAs targeted to the HIV-1 promoter region. J RNAi Gene Silencing. 2005;1(2):66\u201378.","journal-title":"J RNAi Gene Silencing"},{"issue":"10","key":"3089_CR146","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1038\/mtna.2015.31","volume":"4","author":"C Ahlenstiel","year":"2015","unstructured":"Ahlenstiel C, et al. Novel RNA duplex locks HIV-1 in a latent state via Chromatin-mediated transcriptional Silencing. Mol Ther Nucleic Acids. 2015;4(10):e261.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"3089_CR147","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.70121","volume":"105","author":"A Zubair","year":"2025","unstructured":"Zubair A, et al. Current challenges with highly active antiretroviral therapy and new hope and horizon with CRISPR-CAS9 technology for HIV treatment. Chem Biol Drug Des. 2025;105(5):e70121.","journal-title":"Chem Biol Drug Des"},{"issue":"4","key":"3089_CR148","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/aid.2011.0017","volume":"27","author":"DM Margolis","year":"2011","unstructured":"Margolis DM. Eradication therapies for HIV infection: time to begin again. AIDS Res Hum Retroviruses. 2011;27(4):347\u201353.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"3089_CR149","doi-asserted-by":"publisher","DOI":"10.1007\/s10989-025-10702-5","volume":"31","author":"A Zubair","year":"2025","unstructured":"Zubair A, Ali M, Akhtar N. HIV-1 nef gene characterization and subtype analysis in Pakistan: a molecular docking approach with Mastoparan-L peptide. Int J Pept Res Ther. 2025;31(3):46.","journal-title":"Int J Pept Res Ther"},{"issue":"1","key":"3089_CR150","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12977-022-00600-9","volume":"19","author":"LC da Costa","year":"2022","unstructured":"da Costa LC, et al. Repression of HIV-1 reactivation mediated by CRISPR\/dCas9-KRAB in lymphoid and myeloid cell models. Retrovirology. 2022;19(1):12.","journal-title":"Retrovirology"},{"issue":"5","key":"3089_CR151","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/COH.0000000000000963","volume":"20","author":"MA Moso","year":"2025","unstructured":"Moso MA, et al. CRISPR\/Cas9 for achieving postintervention HIV control. Curr Opin HIV AIDS. 2025;20(5):432\u201340.","journal-title":"Curr Opin HIV AIDS"},{"key":"3089_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/v15091912","author":"JN Howard","year":"2023","unstructured":"Howard JN, Bosque A. IL-15 and N-803 for HIV cure approaches. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15091912.","journal-title":"Viruses"},{"issue":"5","key":"3089_CR153","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/COH.0000000000000641","volume":"15","author":"JD Gunst","year":"2020","unstructured":"Gunst JD, H\u00f8jen JF, S\u00f8gaard OS. Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission. Curr Opin HIV AIDS. 2020;15(5):309\u201315.","journal-title":"Curr Opin HIV AIDS"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03089-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03089-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03089-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:59:49Z","timestamp":1772024389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03089-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":153,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3089"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03089-2","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not relevant.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"52"}}